Table 2.

Mouse models of glial depletion and their epithelial phenotypes.

Approach		Method	Timing	EGC loss		Barrier integrity	Transport function	Epithelial proliferation	inflammation	Motility	References
Chemical	6-AN	Single IP dose	p1-p11	X	MP EGCs present but abnormal	X	NR	NR	X	NR	[32]
	Fluorocitrate	Daily IP x 7 days	Adult	X	MP EGCs present but abnormal	X	NR	NR	X	✓	[40]
Genetic	hGFAP-HA; CL4-TCR		Constitutive	✓	↑ # GFAP+ cells in MP and SMP	✓	NR	NR	✓	NR	[35]
	hGfapCre/ERT2; Rosa26iDTR	Single dose of TAM followed by two IP doses of DT (12-18h later)	p6-p7	✓	↑ GFAP IR	X	NR	NR	X	✓	[37]
	Pip1Cre/ERT2; Rosa26iDTR			✓	↑ GFAP IR	X	NR	NR	X	✓
	Sox10Cre/ERT2; Rosa26iDTR			✓	↑ GFAP IR	X	NR	NR	X	✓
	hGFAP-HSV-Tk	Continuous GCV (100m g/kg/day)	Adult	✓	↑ GFAP IR in MP	✓	NR	NR	✓	NR	[33], [34]
	hGFAP-HSV-Tk transgenic	IP GCV (25mg/kg) twice a week		✓	↑ GFAP IR and protein	X	NR	X	X	NR	[41]
	hGFAP-HA	Adoptive transfer of activated HA-specific CD8+ T cells		✓	↑ GFAP IR in MP	✓	✓	NR	X	✓	[36]
	hGfapCre; Rosa26iDTR	Intracolonic DT injection		✓	↑ GFAP IR and protein levels	NR	NR	NR	NR	NR	[41]
	hGfapCre/ERT2; Rosa26DTA	Single IP dose (2mg) TAM and then continuous in chow		✓	↑ GFAP IR in MP	X	NR	✓	X	NR	[38]
	Plp1Cre/ERT2; Rosa26DTA	Single oral dose of TAM (8mg)		✓	↑ #S100β+ cells in MP, muscuiaris externa and mucosa ↑ GFAP IR in MP	X	NR	X	X	✓	[34]
	Plp1Cre/ERT2; Rosa26iDTR	4-OHT 1.5mg IP x 2 doses; Intracolonic injection of 20ng DT		NR	NR	NR	NR	NR	NR	NR	[41]
	Plp1Cre/ERT2; Rosa26DTA	Single IP dose (2mg) TAM and then continuous in chow		✓	↑ Plp1 mRNA and Plp1-Tomato+ cells	X	NR	X	X	NR	[38]
	Plp1Cre/ERT2; hGfapCre/ERT2; Rosa26DTA			NR	NR	✓	NR	NR	✓	NR

✓ – Yes, phenotype observed; X – No, phenotype not observed; NR – not reported; IP – intraperitoneal; GCV – ganciclovir; TAM – Tamoxifen; IR – immunoreactivity; MP – myenteric plexus; SMP – submucosal plexus.